{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:07:24Z","timestamp":1791320844427,"version":"4.3.1"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>In this study, we evaluate the predictors of treatment outcomes in drug resistant tuberculosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>An observational retrospective study was conducted by using the medical records of patients confirmed for TB at Kasturba Medical College from January 2015 to December 2018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Four hundred and sixty-two TB patients were included in this study. Of the total TB-confirmed patients, about 85.1% are diagnosed with pulmonary TB (PTB) (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 393), 11.7% were extrapulmonary tuberculosis (EPTB) (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 54), and 3.2% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 15) cases had both PTB and EPTB. Among the 462 cases, the frequency of multidrug-resistant TB (MDR-TB) was 25% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 117), extensively drug-resistant TB was 1% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 3), and non-MDR cases were 74% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 342). The frequency of unsuccessful treatment outcome was 92.9% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 429) and successful outcome was 7.1% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 33). There were 68.2% of new and 31.8% retreatment cases of TB. HIV co-infection was found in 2.3% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 14) of TB cases, and among them, 64.3% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 9) were found in PTB cases. The major comorbidities found were diabetes (21.2%), weight loss (12.6%), and anemia (12.6%). There was a difference in rate of PTB cases across years decreasing in the year 2017, whereas ETB cases were increasing in the year 2017. The TB treatment success rate was increased from 2015 (4.8%) to 2018 (8.3%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The higher rate of poor treatment outcome emphasizes the need of improvement in TB surveillance, treatment, more stringent follow-up, monitoring, and patient education to ensure complete and successful treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijmy.ijmy_244_21","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T09:02:00Z","timestamp":1682067720000},"page":"38-46","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":21,"title":["Predictors of Treatment Outcomes in Drug Resistant Tuberculosis-Observational Retrospective Study"],"prefix":"10.4103","volume":"11","author":[{"given":"July Mary","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aswini Kumar","family":"Mohapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleena Ummer","family":"Velladath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavitha S","family":"Shettigar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-6-20240902","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"R5-6-20240902","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1056\/NEJM200104263441706","article-title":"Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance","volume":"344","author":"Espinal","year":"2001","journal-title":"N Engl J Med"},{"key":"R6-6-20240902","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1183\/09031936.00214014","article-title":"Towards tuberculosis elimination: An action framework for low-incidence countries","volume":"45","author":"Lonnroth","year":"2015","journal-title":"Eur Respir J"},{"key":"R7-6-20240902","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1183\/09031936.00003710","article-title":"Treatment outcome of multidrug\/extensively drug-resistant tuberculosis in Latvia, 2000-2004","volume":"36","author":"Leimane","year":"2010","journal-title":"Eur Respir J"},{"key":"R8-6-20240902","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1001\/jama.300.18.2153","article-title":"Extensively drug-resistant tuberculosis in the United States, 1993-2007","volume":"300","author":"Shah","year":"2008","journal-title":"JAMA"},{"key":"R9-6-20240902","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4103\/ijmy.ijmy_59_17","article-title":"Treatment outcome of patients having extensively drug-resistant tuberculosis in Gujarat, India","volume":"6","author":"Prajapati","year":"2017","journal-title":"Int J Mycobacteriol"},{"key":"R10-6-20240902","doi-asserted-by":"crossref","first-page":"32","DOI":"10.5588\/pha.16.0055","article-title":"Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India","volume":"7","author":"Nair","year":"2017","journal-title":"Public Health Action"},{"key":"R11-6-20240902","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1183\/09031936.00101814","article-title":"Multidrug-resistant tuberculosis around the world: What progress has been made?","volume":"45","author":"Falzon","year":"2015","journal-title":"Eur Respir J"},{"key":"R12-6-20240902","doi-asserted-by":"crossref","first-page":"e4370","DOI":"10.1371\/journal.pone.0004370","article-title":"Transmission of MDR and XDR tuberculosis in Shanghai, China","volume":"4","author":"Zhao","year":"2009","journal-title":"PLoS One"},{"key":"R13-6-20240902","first-page":"361","article-title":"Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea","volume":"8","author":"Park","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"R14-6-20240902","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4103\/bbrj.bbrj_141_18","article-title":"Pulmonary tuberculosis incidence and drug resistance-related factors analysis in North China","volume":"3","author":"Qi","year":"2019","journal-title":"Biomed Biotechnol Res J"},{"key":"R15-6-20240902","doi-asserted-by":"crossref","first-page":"e6914","DOI":"10.1371\/journal.pone.0006914","article-title":"Treatment outcomes of multidrug-resistant tuberculosis: A systematic review and meta-analysis","volume":"4","author":"Johnston","year":"2009","journal-title":"PLoS One"},{"key":"R16-6-20240902","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/0976-500X.130062","article-title":"Treatment outcome of standardized regimen in patients with multidrug-resistant tuberculosis","volume":"5","author":"Jain","year":"2014","journal-title":"J Pharmacol Pharmacother"},{"key":"R17-6-20240902","first-page":"124","article-title":"Outcome of tuberculosis treatment in Hamburg: A survey, 1997-2001","volume":"7","author":"Diel","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"key":"R19-6-20240902","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1128\/JCM.01916-13","article-title":"Mycobacterium tuberculosis outbreak strain of Danish origin spreading at worrying rates among Greenland-born persons in Denmark and Greenland","volume":"51","author":"Lillebaek","year":"2013","journal-title":"J Clin Microbiol"},{"key":"R20-6-20240902","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.arr.2011.03.003","article-title":"Aging with multimorbidity: A systematic review of the literature","volume":"10","author":"Marengoni","year":"2011","journal-title":"Ageing Res Rev"},{"key":"R21-6-20240902","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0306-4530(97)00080-2","article-title":"The effects of nicotine on the immune system","volume":"23","author":"McAllister-Sistilli","year":"1998","journal-title":"Psychoneuroendocrinology"},{"key":"R22-6-20240902","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12890-018-0600-1","article-title":"Tuberculosis treatment outcome and predictors in northern Ethiopian prisons: A five-year retrospective analysis","volume":"18","author":"Adane","year":"2018","journal-title":"BMC Pulm Med"},{"key":"R23-6-20240902","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1186\/1471-2458-12-537","article-title":"Treatment outcome of smear-positive pulmonary tuberculosis patients in Tigray Region, Northern Ethiopia","volume":"12","author":"Berhe","year":"2012","journal-title":"BMC Public Health"},{"key":"R24-6-20240902","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3855\/jidc.5963","article-title":"Outcome of tuberculosis patients under directly observed short course treatment in western Ethiopia","volume":"9","author":"Ejeta","year":"2015","journal-title":"J Infect Dev Ctries"},{"key":"R25-6-20240902","doi-asserted-by":"crossref","first-page":"e0150560","DOI":"10.1371\/journal.pone.0150560","article-title":"Treatment outcome of tuberculosis patients under directly observed treatment short course and factors affecting outcome in Southern Ethiopia: A five-year retrospective study","volume":"11","author":"Gebrezgabiher","year":"2016","journal-title":"PLoS One"},{"key":"R26-6-20240902","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4103\/bbrj.bbrj_131_19","article-title":"Effectiveness of the shorter MDR regimen in the management of tuberculosis: Shortfall in the outcome of disease a multidimensional approach and evaluation for a better alternative","volume":"4","author":"Das","year":"2020","journal-title":"Biomed Biotechnol Res J"},{"key":"R27-6-20240902","doi-asserted-by":"crossref","first-page":"e73501","DOI":"10.1371\/journal.pone.0073501","article-title":"Adherence to tuberculosis treatment, sputum smear conversion and mortality: A retrospective cohort study in 48 Rwandan clinics","volume":"8","author":"Kayigamba","year":"2013","journal-title":"PLoS One"},{"key":"R28-6-20240902","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1186\/s13104-015-1452-x","article-title":"Adherence to anti-tuberculosis treatment and treatment outcomes among tuberculosis patients in Alamata District, northeast Ethiopia","volume":"8","author":"Tesfahuneygn","year":"2015","journal-title":"BMC Res Notes"},{"key":"R29-6-20240902","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4103\/ijmy.ijmy_170_20","article-title":"Pattern of primary tuberculosis drug resistance and associated risk factors at Dubai health authority in Dubai","volume":"9","author":"Habous","year":"2020","journal-title":"Int J Mycobacteriol"},{"key":"R30-6-20240902","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/thx.2005.045963","article-title":"Risk factors for multidrug resistant tuberculosis in Europe: A systematic review","volume":"61","author":"Faustini","year":"2006","journal-title":"Thorax"},{"key":"R31-6-20240902","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(05)17786-1","article-title":"Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: A retrospective cohort study","volume":"365","author":"Leimane","year":"2005","journal-title":"Lancet"},{"key":"R32-6-20240902","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10096-020-04077-2","article-title":"The prevalence and risks of major comorbidities among inpatients with pulmonary tuberculosis in China from a gender and age perspective: A large-scale multicenter observational study","volume":"40","author":"Kang","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R33-6-20240902","doi-asserted-by":"crossref","first-page":"12995","DOI":"10.1038\/s41598-019-49439-9","article-title":"Predictors for pulmonary tuberculosis treatment outcome in Denmark 2009-2014","volume":"9","author":"Holden","year":"2019","journal-title":"Sci Rep"},{"key":"R34-6-20240902","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4103\/2212-5531.307069","article-title":"Treatment outcomes of patients with tuberculosis and diabetes: A prospective cohort study from India","volume":"10","author":"Desai","year":"2021","journal-title":"Int J Mycobacteriol"},{"key":"R35-6-20240902","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4103\/ijmy.ijmy_132_21","article-title":"Microbiome in sputum as a potential biomarker of chronicity in pulmonary resistant to rifampicin-tuberculosis and multidrug-resistant-tuberculosis patients","volume":"10","author":"Wiqoyah","year":"2021","journal-title":"Int J Mycobacteriol"},{"key":"R36-6-20240902","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.7150\/ijms.53492","article-title":"Sputum microbiota as a potential diagnostic marker for multidrug-resistant tuberculosis","volume":"18","author":"Lin","year":"2021","journal-title":"Int J Med Sci"},{"key":"R37-6-20240902","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S2213-2600(18)30501-0","article-title":"The microbiome and tuberculosis: State of the art, potential applications, and defining the clinical research agenda","volume":"7","author":"Naidoo","year":"2019","journal-title":"Lancet Respir Med"},{"key":"R38-6-20240902","first-page":"BC01","article-title":"Role of anaemia and magnesium levels at the initiation of tuberculosis therapy with sputum conversion among pulmonary tuberculosis patients","volume":"11","author":"Agrawal","year":"2017","journal-title":"J Clin Diagn Res"},{"key":"R39-6-20240902","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41598-018-37860-5","article-title":"Tuberculosis-associated anemia is linked to a distinct inflammatory profile that persists after initiation of antitubercular therapy","volume":"9","author":"Gil-Santana","year":"2019","journal-title":"Sci Rep"},{"key":"R40-6-20240902","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3945\/jn.111.144287","article-title":"Iron deficiency and anemia predict mortality in patients with tuberculosis","volume":"142","author":"Isanaka","year":"2012","journal-title":"J Nutr"},{"key":"R41-6-20240902","first-page":"1224","article-title":"Risk factors for mortality among adult patients with newly diagnosed tuberculosis in Samara, Russia","volume":"10","author":"Kourbatova","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"R42-6-20240902","doi-asserted-by":"crossref","first-page":"e0175278","DOI":"10.1371\/journal.pone.0175278","article-title":"Sustained elevated levels of C-reactive protein and ferritin in pulmonary tuberculosis patients remaining culture positive upon treatment initiation","volume":"12","author":"Miranda","year":"2017","journal-title":"PLoS One"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_244_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:01:45Z","timestamp":1787760105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_244_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmy.ijmy_244_21","relation":{},"ISSN":["2212-5531"],"issn-type":[{"value":"2212-5531","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}